Skip to main content
SpringerLink
Log in

Paper two: Allocation of scarce resources: The need for critical analysis

  • Main Feature
  • Fair And Effective Resource Allocation In Cancer Care: Uncharted Territory?
  • Published:
Health Care Analysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Backhouse, M. E., Backhouse, R. J. and Eddy, S. A. (1992). Economic evaluation bibliography.Health Economics 1 (suppl), 1–235.

    Google Scholar 

  2. Adams, M. E., McCall, N. T., Gray, D. T., Orza, M. J. and Chalmers, T. C. (1992). Economic analysis in randomised controlled trials.Medical Care 30, 231–238.

    Google Scholar 

  3. Gerard, K. (1992). Cost-utility in practise: a policy makers guide to the state of the art.Health Policy 21, 249–279.

    Google Scholar 

  4. Mason, J., Drummond, M. F. and Torrance, G. (1993). Some guidelines on the use of cost-effectiveness league tables.British Medical Journal 306, 570–572.

    Google Scholar 

  5. Drummond, M. F., Brandt, A., Luce, B. and Rovira, J. (1993). Standardising methodologies for economic evaluation in health care.International Journal of Technology Assessment in Health Care 9, 26–36.

    Google Scholar 

  6. Udvarhelyi, S., Colditz, G. A., Rai, A. and Epstein, A. M. (1992). Cost-effectiveness and cost-benefit analyses in the medical literature. Are methods being used correctly?Annals of Internal Medicine 116, 238–244.

    Google Scholar 

  7. Jefferson, T. O. and Demicheli, V. (1994). Is vaccination against Hepatitis B efficient? A review of the world literature.Health Economics,3, 25–38.

    Google Scholar 

  8. Williams, C., Coyle, D., Uyl-de-Groot, C., Gray, A., Hutton, J., Jefferson, T., Karlsson, G., Kesterloot, K. and Wait, S. (1995). Cost-effectiveness in cancer care. European School of Oncology Advisory Report.European Journal of Cancer, in press.

  9. Williams, C. (ed.) (1992).Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems, John Wiley and Sons, Chichester.

    Google Scholar 

  10. Coates, A. S. and Simes, R. J. (1992). Patient assessment of adjuvant treatment in operable breast cancer. In,Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems, ed. by C. Williams, John Wiley and Sons, Chichester.

    Google Scholar 

  11. Department of Health (1992).Assessing the Effects of Health Technology: Principles, Practise and Proposals, Department of Health, London.

    Google Scholar 

  12. Henry, D. (1992). Economic analysis as an aid to subsidization decisions: the development of Australian guidelines for pharmaceuticals.Pharmaco Economics 1, 54–87.

    Google Scholar 

  13. Detsky, A. (1993). Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.Pharmaco Economics 3, 354–361.

    Google Scholar 

  14. Task Force on Principles for Economic Analysis of Health Care Technology (1995). Economic analysis of health care technology: a report on principles.Annals of Internal Medicine 122, 61–70.

    Google Scholar 

  15. Evans, R. G. (1995). Manufacturing consensus, marketing truth: guidelines for economic evaluation.Annals of Internal Medicine 123, 59–60.

    Google Scholar 

  16. Herxheimer, A. (1993). The Cochrane Collaboration. Making the results of controlled trials properly accessible.Postgraduate Medical Journal 69, 863–868.

    Google Scholar 

  17. Moertel, C. G., Fleming, T. R., McDonald, J. F., Haller, D. G., Laurie, J. A. and Tangen, C. (1993). An evaluation of the CEA Test for monitoring patients with resected colon cancer.Journal of the American Medical Association 270, 943–947.

    Google Scholar 

  18. Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lymm, G.et al. (1991). Reduction by granulocyte colony stimulating factor of fever and neutrapenia induced by chemotherapy in patients with small cell lung cancer.New England Journal of Medicine 325, 164–170.

    Google Scholar 

  19. Glaspy, J., Bleecher, G., Gransford, J., Stoller, R. and Strauss, M. (1993). The impact of therapy with filgastrim (recombinant granulocyte colony stimulating factor) on the health care costs associated with cancer chemotherapy.European Journal of Cancer 29A (Suppl 7), 823–830.

    Google Scholar 

  20. Nichols, C. R., Fox, E. P., Roth, B. J., Williams, S. D., Loehner, P. and Einhorn, L. (1994). Incidence of neutrapenic fever in patients treated with standard dose chemotherapy for small cell lung cancer and the cost impact of treatment with granulocyte colony stimulating factor.Journal of Clinical Oncology 12, 1245–1250.

    Google Scholar 

  21. American Federation for Clinical Research National Council (1991).American Federation for Clinical Research Guidelines for Avoiding Conflict of Interest, National Academy Press, Washington D.C.

    Google Scholar 

  22. HMSO (1991).The Health of the Nation: A Strategy for Health in England.

  23. Yusuf, S., Collins, R. and Peto, R. (1984). Why do we need some large, simple, randomised trials.Statistical Medicine 3, 409–420.

    Google Scholar 

  24. Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 32 000 recurrences and 24 000 deaths among 75 000 women.Lancet 337, 1–15 and 71–85.

    Google Scholar 

  25. Begg, C. B. and Berlin, J. A. (1992). Publication bias and dissemination of clinical research. In,Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems, ed. by C. Williams, John Wiley and Sons, Chichester.

    Google Scholar 

  26. Kassider, J. P. and Angell, M. (1994). The journal's policy on cost-effectiveness analyses (editorial).New England Journal of Medicine 331, 667–670.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CRC Wessex Medical Oncology Unit, University of Southampton, Southampton General Hospital, SO16 6YD, Southampton

    Christopher Williams (Senior Lecturer in Medical Oncology)

Authors
  1. Christopher Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, C. Paper two: Allocation of scarce resources: The need for critical analysis. Health Care Anal 4, 28–34 (1996). https://doi.org/10.1007/BF02251143

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02251143

Keywords

Search

Navigation